Characteristics of eligible patients with or without relapsed disease upon diagnosis
| Characteristic . | Relapse (n = 41) . | No relapse (n = 181) . |
|---|---|---|
| Sex | ||
| Male | 23 (56.10) | 76 (41.99) |
| Female | 18 (43.90) | 105 (58.01) |
| Race | ||
| White | 31 (75.60) | 145 (80.11) |
| Black | 4 (9.76) | 19 (10.50) |
| Other | 3 (7.32) | 2 (1.10) |
| Unknown | 3 (7.32) | 15 (8.29) |
| Median age (y) | 15.56 [6.69, 21.76] | 15.25 [3.08, 21.94] |
| Stage | ||
| I | 7 (17.07) | 47 (25.97) |
| II | 34 (82.93) | 134 (74.03) |
| Pathology by central review | ||
| NS | 30 (73.17) | 115 (63.54) |
| MC | 2 (4.88) | 30 (16.57) |
| Missing | 9 (21.95) | 36 (19.89) |
| ESR | ||
| ≤20 | 14 (34.15) | 109 (60.22) |
| >20 | 27 (65.85) | 72 (39.78) |
| CRP | ||
| ≤2× upper limit | 23 (56.10) | 135 (74.59) |
| >2× upper limit | 18 (43.90) | 46 (25.41) |
| Disease sites, n | ||
| 1-2 | 35 (85.37) | 164 (90.61) |
| ≥3 | 6 (14.63) | 17 (9.39) |
| Characteristic . | Relapse (n = 41) . | No relapse (n = 181) . |
|---|---|---|
| Sex | ||
| Male | 23 (56.10) | 76 (41.99) |
| Female | 18 (43.90) | 105 (58.01) |
| Race | ||
| White | 31 (75.60) | 145 (80.11) |
| Black | 4 (9.76) | 19 (10.50) |
| Other | 3 (7.32) | 2 (1.10) |
| Unknown | 3 (7.32) | 15 (8.29) |
| Median age (y) | 15.56 [6.69, 21.76] | 15.25 [3.08, 21.94] |
| Stage | ||
| I | 7 (17.07) | 47 (25.97) |
| II | 34 (82.93) | 134 (74.03) |
| Pathology by central review | ||
| NS | 30 (73.17) | 115 (63.54) |
| MC | 2 (4.88) | 30 (16.57) |
| Missing | 9 (21.95) | 36 (19.89) |
| ESR | ||
| ≤20 | 14 (34.15) | 109 (60.22) |
| >20 | 27 (65.85) | 72 (39.78) |
| CRP | ||
| ≤2× upper limit | 23 (56.10) | 135 (74.59) |
| >2× upper limit | 18 (43.90) | 46 (25.41) |
| Disease sites, n | ||
| 1-2 | 35 (85.37) | 164 (90.61) |
| ≥3 | 6 (14.63) | 17 (9.39) |
Data are the number of patients (percentage of the study group), unless otherwise indicated.
CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; MC, mixed cellularity; NS, nodular sclerosing.